Published On: 5/7/2020
Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
DURHAM, N.C., May 7, 2020 /PRNewswire/ -- TARGET PharmaSolutions, an innovative healthcare data company that generates real-world clinical data and evidence, announced today the latest research findings from its inflammatory bowel disease study (TARGET-IBD), which was published in the May issue of the peer-reviewed journal Gastroenterology.
The abstract, "Objective Disease Activity Assessment and Therapeutic Drug Monitoring (TDM) is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD," was accepted to the annual Digestive Disease Week conference, originally planned to take place in Chicago.
The research aimed to describe the objective marker and therapeutic drug monitoring assessments used in routine clinical practice, prior to biologic therapeutic changes due to loss of response in adult participants. More than 30% of both Crohn's disease and ulcerative colitis patients lacked any type of assessment in the 12 weeks leading up to dose changes; for dose discontinuations, this value was over 20%.
"This analysis brought to light that objective monitoring prior to changes in therapeutics is lacking in many cases," said first author Benjamin Click, MD, staff gastroenterologist at Cleveland Clinic. "Improved understanding of reasons for failure may optimize biologic positioning and outcomes in IBD."
TARGET-IBD is a prospective longitudinal cohort of over 4,000 IBD patients receiving usual care from 34 academic and community centers throughout the U.S. Data is collected retrospectively for three years from the patient's date of consent and then prospectively for at least five years. The resultant robust cohort allows for the collection of effectiveness and safety data upon new drug approvals.
An additional abstract was submitted by TARGET PharmaSolutions for its nonalcoholic steatohepatitis (NASH) study, TARGET-NASH, and was also accepted for publication. Gastroenterology is the official journal of the American Gastroenterological Association Institute.
About TARGET PharmaSolutions
TARGET is a clinical data company that sponsors large disease-specific patient cohorts to generate real-world evidence and provide regulatory-grade data to partners to improve clinical, medical, and commercial outcomes.
The TARGET model creates collaborative communities of distinguished stakeholders around diseases to gain deeper understandings of the natural history and effectiveness of new agents across underrepresented populations.
TARGET has developed seven disease communities: nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), chronic hepatitis B (HBV), and asthma. For more information, visit www.targetpharmasolutions.com.
About TARGET PharmaSolutions
Headquartered in Durham, NC, TARGET PharmaSolutions is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting. TARGET PharmaSolutions has six disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), TARGET-IBD (inflammatory bowel disease), TARGET-DERM (immune mediated skin conditions) and TARGET-HBV (hepatitis B).
For more information, visit www.targetpharmasolutions.com.
984.234.0268 ext 205
05/07/2020Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
04/14/2020TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
03/17/2020TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
03/13/2020TARGET PharmaSolutions Launches Real-World Asthma Study